眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

2022更新版—2017 NICE指南：青光眼的诊断和管理

2022-01-26 英国国家卫生与临床优化研究所 NICE官网

青光眼

2022年1月，英国国家卫生与临床优化研究所 (NICE)更新了青光眼的诊断和管理指南。

中文标题：

2022更新版—2017 NICE指南：青光眼的诊断和管理

英文标题：

NICE guideline [NG81]:Glaucoma: diagnosis and management

发布机构：

英国国家卫生与临床优化研究所

发布日期：

2022-01-26

简要介绍：

2022年1月，英国国家卫生与临床优化研究所 (NICE)更新了青光眼的诊断和管理指南。文章主要涵盖了年龄≥18岁人群青光眼的诊断和管理，202年主要更新了高眼压和慢性开角型青光眼的治疗和护理建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022更新版—2017 NICE指南：青光眼的诊断和管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=05dfb1c0023a0890, title=2022更新版—2017 NICE指南：青光眼的诊断和管理, enTitle=NICE guideline [NG81]:Glaucoma: diagnosis and management, guiderFrom=NICE官网, authorId=0, author=, summary=2022年1月，英国国家卫生与临床优化研究所 (NICE)更新了青光眼的诊断和管理指南。, cover=https://img.medsci.cn/2022127/1643270356580_1608702.jpg, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所（NICE，National Institute for Health and Clinical Excellence）是NHS的组织，设在伦敦和曼彻斯特。NICE成立于1999年4月1日，目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南，设定质量标准，管理国家数据库，为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Wed Jan 26 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年1月，英国国家卫生与临床优化研究所 (NICE)更新了青光眼的诊断和管理指南。文章</span><span style="color: #373737;">主要涵盖了年龄&ge;18岁人群青光眼的诊断和管理，202年主要更新了高眼压和慢性开角型青光眼的治疗和护理建议。</span></p>, tagList=[TagDto(tagId=9772, tagName=青光眼)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7551, appHits=243, showAppHits=0, pcHits=792, showPcHits=7308, likes=2, shares=43, comments=9, approvalStatus=1, publishedTime=Thu Jan 27 15:52:40 CST 2022, publishedTimeString=2022-01-26, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Thu Jan 27 16:02:41 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Thu Jan 04 17:59:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022更新版—2017 NICE指南：青光眼的诊断和管理.pdf)])
2022更新版—2017 NICE指南：青光眼的诊断和管理.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2162917, encodeId=17f0216291e71, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/ef077573df6440a0808ec5502406358a/681e9030774647e5aa92d6eb167285fc.jpg, createdBy=c7d66529078, createdName=不要当猪, createdTime=Sun Oct 15 19:41:12 CST 2023, time=2023-10-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212272, encodeId=ceb812122e24b, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:55:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195212, encodeId=6c881195212eb, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=946f6512065, createdName=ms3000001996934587, createdTime=Sat Feb 19 22:34:27 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191762, encodeId=76cb1191e6260, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=778c3261438, createdName=12d1cb19m20暂无昵称, createdTime=Thu Feb 10 11:52:57 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190818, encodeId=5821119081823, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:11:57 CST 2022, time=2022-02-07, status=1, ipAttribution=)]
    2023-10-15 不要当猪 来自四川省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2162917, encodeId=17f0216291e71, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/ef077573df6440a0808ec5502406358a/681e9030774647e5aa92d6eb167285fc.jpg, createdBy=c7d66529078, createdName=不要当猪, createdTime=Sun Oct 15 19:41:12 CST 2023, time=2023-10-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212272, encodeId=ceb812122e24b, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:55:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195212, encodeId=6c881195212eb, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=946f6512065, createdName=ms3000001996934587, createdTime=Sat Feb 19 22:34:27 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191762, encodeId=76cb1191e6260, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=778c3261438, createdName=12d1cb19m20暂无昵称, createdTime=Thu Feb 10 11:52:57 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190818, encodeId=5821119081823, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:11:57 CST 2022, time=2022-02-07, status=1, ipAttribution=)]
    2022-04-18 14863d7cm33暂无昵称

    很棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2162917, encodeId=17f0216291e71, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/ef077573df6440a0808ec5502406358a/681e9030774647e5aa92d6eb167285fc.jpg, createdBy=c7d66529078, createdName=不要当猪, createdTime=Sun Oct 15 19:41:12 CST 2023, time=2023-10-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212272, encodeId=ceb812122e24b, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:55:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195212, encodeId=6c881195212eb, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=946f6512065, createdName=ms3000001996934587, createdTime=Sat Feb 19 22:34:27 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191762, encodeId=76cb1191e6260, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=778c3261438, createdName=12d1cb19m20暂无昵称, createdTime=Thu Feb 10 11:52:57 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190818, encodeId=5821119081823, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:11:57 CST 2022, time=2022-02-07, status=1, ipAttribution=)]
    2022-02-19 ms3000001996934587

    感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2162917, encodeId=17f0216291e71, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/ef077573df6440a0808ec5502406358a/681e9030774647e5aa92d6eb167285fc.jpg, createdBy=c7d66529078, createdName=不要当猪, createdTime=Sun Oct 15 19:41:12 CST 2023, time=2023-10-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212272, encodeId=ceb812122e24b, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:55:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195212, encodeId=6c881195212eb, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=946f6512065, createdName=ms3000001996934587, createdTime=Sat Feb 19 22:34:27 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191762, encodeId=76cb1191e6260, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=778c3261438, createdName=12d1cb19m20暂无昵称, createdTime=Thu Feb 10 11:52:57 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190818, encodeId=5821119081823, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:11:57 CST 2022, time=2022-02-07, status=1, ipAttribution=)]
    2022-02-10 12d1cb19m20暂无昵称

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2162917, encodeId=17f0216291e71, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/ef077573df6440a0808ec5502406358a/681e9030774647e5aa92d6eb167285fc.jpg, createdBy=c7d66529078, createdName=不要当猪, createdTime=Sun Oct 15 19:41:12 CST 2023, time=2023-10-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212272, encodeId=ceb812122e24b, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:55:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195212, encodeId=6c881195212eb, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=946f6512065, createdName=ms3000001996934587, createdTime=Sat Feb 19 22:34:27 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191762, encodeId=76cb1191e6260, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=778c3261438, createdName=12d1cb19m20暂无昵称, createdTime=Thu Feb 10 11:52:57 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190818, encodeId=5821119081823, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:11:57 CST 2022, time=2022-02-07, status=1, ipAttribution=)]
    2022-02-07 245462683

    谢谢提供

    0

相关指南

美国青光眼协会立场文件：微创青光眼手术

美国青光眼协会 (AGS) · 2021-11-01

2021 EGS青光眼术语和指南（第5版）

欧洲青光眼学会(EGS,European Glaucoma Society) · 2021-06-01

中国青光眼指南（2020年）

中华医学会眼科学分会青光眼学组 · 2020-08-30

我国青光眼临床诊断和治疗描述性术语专家建议（2018年）

中华医学会眼科学分会青光眼学组 · 2018-03-10

我国基于MRI的改良视神经蛛网膜下腔间隙垂直截面积测量方法专家共识(2017年)

中华医学会眼科学分会青光眼学组 · 2017-04-30

我国微导管辅助的360°小梁切开术专家共识（2017年）

中华医学会眼科学分会 · 2017-03-30